




Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study

Ana Filipa Fonseca¹Raquel Lahoz¹ Clare Proudfoot¹Stefano Corda¹Emil Loefroth¹James Jackson² Sarah Cotton² Rachel Studer¹ ¹Novartis Pharma AG, Basel, Switzerland;²Adelphi Real World, Bollington, UK

Purpose: To characterize symptoms, clinical burden, and health-related quality of life (HRQoL) among women and men with heart failure (HF) with a left ventricular ejection fraction (LVEF) of $\leq 60\%$ in Europe.

Patients and Methods: A real-world cross-sectional study was conducted in France, Germany, Italy, Spain, and United Kingdom from June to November 2019. Patient record forms were completed by 257 cardiologists and 158 general practitioners for consecutive patients with HF. The same patients were invited to complete a questionnaire comprising patient-reported outcomes: the Minnesota Living with Heart Failure Questionnaire (MLHFQ), five-level five-dimension EuroQol questionnaire (EQ-5D-5L), Visual Analogue Scale (VAS), and Work Productivity and Activity Impairment questionnaire.

Results: The mean age of 804 patients (men, $n=517$; women, $n=287$) was 68.6 years (men, 67.8 years; women, 70.2 years; $p=0.0022$). The mean LVEF was 44.7% (men, 43.6%; women, 46.8%; $p<0.0001$). Patients reported dyspnoea when active (overall, 55.7%; men, 56.0%; women, 55.3%), fatigue/weakness/faintness (34.5%; men, 32.9%; women, 37.2%), and oedema (20.3%; men, 18.7%; women, 23.1%) as the most troublesome HF symptoms. Overall, 54.1% of patients reported low mood/depression (men, 50.8%; women, 60.1%). The overall MLHFQ mean score was higher (ie, poorer HRQoL) among women vs men (37.9 vs 34.6; $p=0.0481$). MLHFQ was consistently higher (ie, poorer HRQoL) for women vs men across the physical (18.6 vs 16.6; $p=0.0041$) and emotional (9.4 vs 7.9; $p=0.0021$) scoring domains. Mean EQ-5D utility (0.69 vs 0.75; $p=0.0046$) and VAS scores (55.4 vs 61.3; $p<0.0001$) were lower among women compared with men. Overall, 23.4% of patients were hospitalized owing to HF in the previous year (men, 22.7%; women, 24.6%). Patients reported 43.2% activity impairment due to HF (men, 41.6%; women, 46.4%; $p=0.01$).

Conclusion: HF causes a substantial burden on patients, with a greater burden among women vs men. This gender-related difference is consistent with other HF studies, warranting further research to understand the underlying reasons.

Keywords: burden, gender, heart failure, health-related quality of life, real-world, work productivity

Introduction

Heart failure (HF) is a chronic disease characterized by the reduced ability of the heart to pump and/or fill up with blood.¹ HF is a serious public health problem affecting an estimated 40 million people worldwide² and more than 15 million people in Europe.³ Given that the world's ageing population is growing and that HF is more prevalent with age, HF prevalence has also been estimated to increase

Correspondence: Ana Filipa Fonseca
Real World Evidence Group, Cardio-
Renal-Metabolic Franchise, Novartis
Pharma AG, Novartis Campus, Basel,
CH-4002, Switzerland
Tel: +41 (0) 793489979
Email ana_filipa.fonseca@novartis.com

further, with a 40% projected rise between 2015 and 2035.⁴ Thus, HF is likely to become one of the world's most prevalent chronic conditions.

HF is a progressive and symptomatic disease and has an adverse impact on patients' lives. Patients with HF experience various physical and emotional symptoms, including shortness of breath (dyspnoea), fatigue, swelling of the ankles or abdomen, sleep difficulties, depression, and chest pain.^{1,5} HF is associated with high morbidity and poor prognosis, to an extent similar to cancer,⁶ and substantially impacts patients' health-related quality of life (HRQoL), with nearly 75% of patients reporting difficulties in performing activities of daily living.⁷ The devastating nature of HF can make patients dependent on caregivers and lead to social isolation, anxiety, and depression.⁸ Patients with HF have a markedly reduced HRQoL compared with those with other chronic diseases and the healthy population.^{9,10} A poorer HRQoL in HF patients is associated with increased hospitalizations and death, with approximately 3 million hospitalizations and numerous deaths reported in Europe annually.³ The financial burden of HF is substantial, and contributes to 1–2% of the total healthcare expenditure in Europe.^{8,11} Some evidence also suggests that the negative impact of HF on the HRQoL of women is greater vs men, with emotional well-being and mental health being more impaired in women vs men.^{9,12–14}

The disease burden in patients with HF with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] <40%) has been studied extensively, and some therapies have shown benefits in the treatment of HFrEF.¹ A few randomized controlled trials have shown evidence of effectiveness in patients with a higher LVEF, including CHARM (LVEF >40%)¹⁵ and PARAGON-HF (LVEF ≥45%).¹⁶ Data from the PARAGON-HF trial showed an interaction between LVEF and treatment effect, with patients with an LVEF below the trial median of 57% deriving a greater benefit than those with an LVEF above this level. Such data have provoked interest in considering HF patients with an LVEF below the normal level (typically considered as an LVEF of approximately 55%–60%, with sex-specific differences) as a population who may benefit from the currently available pharmacotherapies, such as sacubitril/valsartan.¹⁷

In this study, we selected patients with HF with a sub-normal or reduced LVEF, applying a threshold of LVEF ≤60%. The European Society of Cardiology (ESC) defines patients based on LVEF as HFrEF (LVEF <40%), HF with

mid-range EF (LVEF 40–49%) and HF with preserved EF (LVEF ≥50%),¹ however, HF is a heterogeneous disease with a spectrum of phenotypes with overlapping and distinct characteristics.¹⁸ The understanding of HF and classification of HF phenotypes continues to evolve.^{17,18} Recently, the Food and Drug Administration of the United States approved an expanded indication for sacubitril/valsartan in chronic HF,¹⁹ recognizing the benefit particularly in patients with a sub-normal LVEF, as shown in the PARAGON-HF¹⁶ and PARADIGM-HF²⁰ studies. This study was aimed at better understanding a population with an LVEF below normal, defined here as LVEF ≤60%, which has the greatest potential to benefit from sacubitril/valsartan. There is a lack of evidence on the burden in the overall population of HF patients with a sub-normal LVEF, and information by sex is scarce. For these reasons, we aimed to assess the symptoms, clinical burden, and HRQoL among patients with HF with an LVEF of ≤60% from both the patient and physician perspective in a real-world setting of five countries from Europe. We also aimed to investigate whether differences existed in the symptoms, clinical burden, and HRQoL between men and women with HF. The findings from this study will also help to inform health policy makers on the current burden of HF prevailing in Europe.

Materials and Methods

Study Design

The Adelphi Disease Specific Programme (DSP)TM is a large multinational survey conducted in clinical practice that describes patient characteristics, current disease management, impact of the disease burden, and associated treatment effects. The DSPTM methodology has been published previously.^{21–23} This was a cross-sectional survey of patients with HF conducted in a real-world setting in France, Germany, Italy, Spain, and the United Kingdom from June to November 2019.

The HF DSPTM incorporates four questionnaires: a physician survey, a patient record form, a patient self-completion questionnaire, and a caregiver self-completion questionnaire. Physicians were included if they were cardiologists or general practitioners (GPs), were actively involved in managing HF patients (ie, monthly treatment of ≥16 patients with HF for cardiologists and eight patients with HF for GPs), and consented to participate. All components completed by the physician were online. Physicians completed patient record forms for eight

consecutive HF patients who consulted them, using data from medical records. Patient self-completion questionnaires were voluntarily completed by the patients whose information was recorded in the patient record forms.

The study was conducted in accordance with the ethical principles as per the Declaration of Helsinki. Since this study involved the participation of human subjects, the protocol was submitted to the Western International Review Board (study protocol number 8649). However, a waiver was provided by the Board because the study aimed to improve understanding rather than testing hypotheses and the ethical approval was not considered necessary. Informed consents were obtained from physicians, patients, and caregivers before the start of study.

Patient Selection

Consecutive patients from the same physicians were included if they were aged ≥ 18 years, had a confirmed diagnosis of HF, and consented to voluntarily fill the patient self-completion questionnaire. Patients who were involved in any clinical trial were not included.

Study Measures

Physician surveys captured data on type of practice, including information on the aetiology and management of HF and awareness/adherence to local/national HF guidelines. Physician-completed patient record forms included data on patient demographics, symptoms of HF, disease severity, treatment patterns, satisfaction with care, comorbidities, and healthcare resource use. Information collected in the patient self-completion questionnaire comprised demographics, lifestyle, disease awareness, common symptoms of HF and how troublesome they were, disruption in patients' everyday life, caregiving assistance required, impact of HF on work productivity and HRQoL, and economic burden. Disruption in patients' everyday life was measured on a scale of 1 ("no disruption at all") to 10 ("severe disruption").

HRQoL was measured using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the five-level five-dimension EuroQol questionnaire (EQ-5D-5L). MLHFQ is an HF-specific questionnaire, consisting of 21 items rated on a six-point Likert scale, and provides an overview of the degree of impact on a patient's HRQoL due to HF (scores of 0 [none] to 5 [very much]). The MLHFQ yields a total score (range: 0–105, from best to worst HRQoL), and scores for two dimensions: physical (range: 0–40) and emotional

(range: 0–25).²⁴ EQ-5D is a generic instrument consisting of a five-question descriptive system (EQ-5D index) and a 100-point visual analogue scale (EQ-5D VAS).^{25,26} The EQ-5D descriptive system measures five dimensions of the health status, ie, mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, using five levels per dimension (no, slight, moderate, severe, and extreme problems).²⁷ The validity and reliability of the EQ-5D as an outcome measure in HF has been published.²⁸ In line with the National Institute for Health and Care Excellence (NICE) guidelines, the EQ-5D-5L scores were cross-walked to the EQ-5D-3L scores.²⁹

Clinical burden was assessed in terms of patients' visits to a doctor or hospitalization in the last 12 months. The impact on work productivity was measured using the Work Productivity and Activity Impairment (WPAI) survey comprising six questions, with the first one being on employment status and the remaining on the assessment of work time missed and work and activity impairment owing to HF in the last 7 days.³⁰

Data Analysis

After the survey, anonymized, aggregated data were received and analyzed. Descriptive statistics were reported as frequency and/or percentages for categorical variables and as mean, standard deviation (SD), median, range, and first and third quartiles for continuous variables. Data for missing values were not imputed. All data were analyzed using UNICOM® Intelligence Reporter version 7.5, a database creation software (IBM® SPSS® Statistics version 25). Statistical tests to demonstrate the difference between both genders included the Fisher's Exact test, Mann-Whitney test, and Pearson's chi-square test. The value of $p < 0.05$ was considered significant.

Results

In total, 415 physicians participated in this study (257 cardiologists and 158 GPs). They completed patient record forms for 3316 patients with HF (2479 of these have LVEF $\leq 60\%$). Of the 3316 patients, 2019 (61%) were attended by cardiologists and 1297 (39%) were attended by GPs. Approximately one-third ($n=1062$; 32.0%) of the patients for whom a patient record form was completed by a physician also completed a patient self-completion questionnaire. Of these 1062 patients, 804 had HF with an LVEF of 60% or lower.

Physician Characteristics

Of the 257 cardiologists, 45% were specialized in non-invasive/non-interventional cardiology, 27% in HF cardiology, and 17% in invasive/interventional cardiology. Cardiologists attended most of their patients in a public hospital (59% of patients), followed by a public office (24%), and a private hospital/public office (17%). Nearly three-quarters of the GPs (72%) had a special interest in HF. GPs largely saw their patients in a public (72% of patients) vs private office (23%).

Patient Demographics and Baseline Clinical Characteristics

Of the 804 patients, 64.3% (n=517) were men. The mean age of patients was 68.6 years; women being significantly older than men (70.2 vs 67.8 years; $p<0.0022$). The mean body mass index for all patients was 27.8 kg/m² and was higher in men vs women (27.9 vs 27.6 kg/m²; $p=0.025$). Overall, 11.6% of patients were current smokers and 22.4% were current consumers of alcohol. Both habits were significantly higher among men compared with women ($p<0.0001$) (Table 1). More women were living alone vs men (32.1% vs 16.4%). Most (83.0%) patients were in the New York Heart Association (NYHA) function classes II and III, with no remarkable difference across both genders. The mean (SD) LVEF for all patients was 44.7% (9.8%), with a significantly greater LVEF in women vs men (46.8% vs 43.6%; $p<0.001$). Hypertension (55.1%), hyperlipidaemia (36.2%), and atrial fibrillation (20.0%) were the most common comorbidities in both genders (Table 1).

Common Symptoms of HF

The most common current symptoms experienced by HF patients included shortness of breath when active (73.0%), fatigue/weakness/faintness (58.0%), oedema (42.0%), and nocturia (25.0%). Fatigue/weakness, oedema, and palpitations were higher among women compared with men (Figure 1). Shortness of breath when active (56.0%), fatigue/weakness (35.0%), and oedema (20.0%) were reported as the most troublesome symptoms by patients; fatigue/weakness/faintness and oedema were more frequently reported as the most troublesome symptoms by women vs men (Figure 1).

Disruption in Patient's Everyday Life Due to HF

On a scale from 1 (no disruption) to 10 (severe disruption), patients (n=757) gave a mean (SD) score of 4.9 (2.4) to

indicate the level of disruption in their everyday life. Women and men reported similar levels of disruption in their lives due to HF, with no significant difference in the mean (SD) scores across both genders (men [n=487]: 4.8 [2.3]; women [n=270]: 5.0 [2.4]; $p=0.4987$). Overall 64% of patients required support from their family or professional caregivers to perform everyday activities (men: 62%; women: 67%).

More than half of the patients (54.1%) reported that they experienced low mood/depression due to HF either sometimes, often, or always, with a higher proportion of women experiencing low mood/depression vs men (60.1% vs 50.8%) (Figure 2A). A significantly higher proportion of women compared with men reported anxiety due to HF ($p=0.0004$), with 62.4% of women experiencing anxiety due to HF either sometimes, often, or always compared with 52.2% of men (Figure 2B).

Impact of HF on Patients' HRQoL MLHFQ Scores

The overall MLHFQ mean score was 35.8, with a significantly higher score (indicative of poorer HRQoL) observed in women vs men (37.9 vs 34.6; $p=0.0481$) (Table 2). The HRQoL was consistently poorer for women across the physical and emotional scoring domains as well ($p=0.0041$ and 0.0021 , respectively).

EQ-5D Scores

We observed significantly lower mean EQ-5D index (0.69 vs 0.75; $p=0.0046$) and EQ-5D VAS scores (55.4 vs 61.3; $p<0.0001$) among women vs men, indicating lower HRQoL (Table 2).

Impact of HF on the Work Productivity of Patients

As shown in Table 1, majority of patients were retired (68.9%) and 17.7% (n = 141) were working, including 12.7% who were working full-time (men: 16.0%; women: 6.7%). Results show that HF impacted the productivity of the patients among the working population. Based on responses to the WPAI questionnaire (Table 3), patients reported that 27.4% of their time at work was impaired owing to HF in the past 7 days; they missed, on average, 9.6% of work time; and they experienced 29.1% of overall work impairment due to HF. No significant differences were observed in the WPAI scores by gender. Among all patients, regardless of their working status (N=725), 43.2% of activity impairment due to HF

Table I Patient Demographics and Baseline Clinical Characteristics

	Overall (N=804)	Men (n=517)	Women (n=287)	P-value
Age (years), mean (SD)	68.62 (11.52)	67.77 (11.22)	70.15 (11.9)	0.0022
Body mass index (kg/m²), mean (SD)	27.79 (4.49)	27.91 (4)	27.57 (5.27)	0.025
Ethnicity, n (%)	N=804	N=517	N=287	0.7959
White/Caucasian	760 (94.53)	493 (95.36)	267 (93.03)	
Asian-Indian subcontinent	3 (0.37)	2 (0.39)	1 (0.35)	
Asian – other	2 (0.25)	1 (0.19)	1 (0.35)	
Chinese	1 (0.12)	1 (0.19)	0 (0.00)	
Hispanic/Latino	10 (1.24)	6 (1.16)	4 (1.39)	
Middle Eastern	15 (1.87)	8 (1.55)	7 (2.44)	
Mixed race	3 (0.37)	1 (0.19)	2 (0.70)	
Afro-Caribbean (EU)	10 (1.24)	5 (0.97)	5 (1.74)	
Smoking status, n (%)	N=794	N=512	N=282	<0.0001
Current smoker	92 (11.59)	71 (13.87)	21 (7.45)	
Ex-smoker	351 (44.21)	278 (54.30)	73 (25.89)	
Never smoked	351 (44.21)	163 (31.84)	188 (66.67)	
Alcohol consumption, n (%)	N=774	n=503	n=271	<0.0001
Drinks alcohol currently	173 (22.35)	140 (27.83)	33 (12.18)	
Used to drink earlier	316 (40.83)	230 (45.73)	86 (31.73)	
Never drunk alcohol	285 (36.82)	133 (26.44)	152 (56.09)	
Living status n (%)	N=804	N=517	N=287	<0.0001
Alone	177 (22.01)	85 (16.44)	92 (32.06)	
With spouse/partner	569 (70.77)	407 (78.72)	162 (56.45)	
With other family	41 (5.10)	15 (2.90)	26 (9.06)	
With friends	4 (0.50)	3 (0.58)	1 (0.35)	
Sheltered home	6 (0.75)	3 (0.58)	3 (1.05)	
Nursing home	4 (0.50)	3 (0.58)	1 (0.35)	
Other	3 (0.37)	1 (0.19)	2 (0.70)	
Time since HF diagnosis (years), mean (SD)	3.49 (4.28) (N=717)	3.57 (4.29) (n=460)	3.36 (4.27) (n=257)	0.2604
Current LVEF of patients, mean (SD)	44.7% (9.8%)	43.6% (9.7%)	46.8% (9.8%)	<0.0001
NYHA functional class[#], n (%)	N=804	N=517	N=287	0.6968
I	117 (14.55)	70 (13.54)	47 (16.38)	
II	502 (62.44)	328 (63.44)	174 (60.63)	
III	165 (20.52)	107 (20.70)	58 (20.21)	
IV	20 (2.49)	12 (2.32)	8 (2.79)	
Employment status, n (%)	N=795	n=512	n=283	<0.0001
Retired	548 (68.93)	363 (70.90)	185 (65.37)	
Working full-time	101 (12.70)	82 (16.02)	19 (6.71)	
Homemaker	50 (6.29)	1 (0.20)	49 (17.31)	
Working part-time	40 (5.03)	26 (5.08)	14 (4.95)	
On long-term sick leave	27 (3.40)	22 (4.30)	5 (1.77)	
Unemployed	27 (3.40)	18 (3.52)	9 (3.18)	
Student	2 (0.25)	0 (0.00)	2 (0.71)	
Common comorbidities, n (%)	N=804	N=517	N=287	
Hypertension	443 (55.10)	282 (54.55)	161 (56.10)	0.7115
Hyperlipidemia	291 (36.19)	193 (37.33)	98 (34.15)	0.3997

(Continued)

Table 1 (Continued).

	Overall (N=804)	Men (n=517)	Women (n=287)	P-value
Atrial fibrillation	161 (20.02)	98 (18.96)	63 (21.95)	0.313
Anxiety	154 (19.15)	95 (18.38)	59 (20.56)	0.4556
Diabetes without chronic complications	136 (16.92)	90 (17.41)	46 (16.03)	0.6946
Coronary heart/artery disease	126 (15.67)	92 (17.79)	34 (11.85)	0.0262
Depression	124 (15.42)	66 (12.77)	58 (20.21)	0.0059
Treatments, n (%)	N=804	N=517	N=287	
β-blockers	582 (72.39)	385 (74.47)	197 (68.64)	0.0839
Diuretics	531 (66.04)	333 (64.41)	198 (68.99)	0.2136
ACE inhibitors	457 (56.84)	294 (56.87)	163 (56.79)	1
Cholesterol medications	354 (44.03)	241 (46.62)	113 (39.37)	0.0538
Antiplatelets	237 (29.48)	170 (32.88)	67 (23.34)	0.0047
Mineral receptor antagonists	193 (24.00)	127 (24.56)	66 (23.00)	0.6668
Angiotensin receptor blockers	187 (23.26)	122 (23.60)	65 (22.65)	0.7942
Anticoagulants	163 (20.27)	101 (19.54)	62 (21.60)	0.5218
Calcium channel blockers	143 (17.79)	88 (17.02)	55 (19.16)	0.4432
Sacubitril/valsartan	98 (12.19)	67 (12.96)	31 (10.80)	0.4311
No HF treatment	28 (3.48)	17 (3.29)	11 (3.83)	0.6916

Notes: #NYHA class is based on patient record forms data but only for the patients who completed a patient self-completion questionnaire. The p values in bold indicate statistically significant difference ($p < 0.05$).

Abbreviations: ACE, angiotensin-converting enzyme; EU, European Union; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation.

was reported, with a significantly greater activity impairment reported in women vs men (46.4% vs 41.4%; $p = 0.01$) (Table 3).

Clinical Burden of HF

Patients reported visiting a doctor owing to HF 4.7 times on an average during the last 12 months, with a similar number of visits between women and men (Table 4). Based on data from patient record forms, 30.7% of patients were hospitalized at least once for any cause and 23.4% were hospitalized due to HF. A higher proportion of women compared with men were hospitalized at least once for any cause as well as owing to HF. The mean (SD) number of hospitalizations for any cause (0.54 [0.99] vs 0.46 [0.97]) and those owing to HF (0.38 [0.85] vs 0.32 [0.83]) were also higher among women vs men. Worsening or uncontrolled HF symptoms were the most common reason for hospitalizations for HF (79% of all HF-related hospitalizations); this occurred more frequently in women compared with men (82% vs 78%). On average, patients spent 5.3 nights in the hospital per visit in the last 12 months, with no significant difference by gender (Table 4).

Patient Treatments and Compliance

Information on treatments used at the time of data collection showed that β-blockers, diuretics, and angiotensin-converting enzyme (ACE) inhibitors were the most common therapies among these patients, with use of β-blockers being numerically higher among men versus women (74.5% vs 68.6%) whereas the use of diuretics was numerically greater among women (64.4% vs 69.0%). Of note, the use of antiplatelet therapies was significantly higher among men compared with women (32.9% vs 23.3%; $p = 0.0047$). The use of other treatments appeared to be similar among both sexes (Table 1).

The data on compliance to treatments indicated no significant differences between men and women. Physician-reported data revealed that 77.5% of overall patients were fully compliant (who took >80% of prescribed dose) to their HF treatments (men, 76.6%; women, 79.0%). Patient-reported data showed that a large majority of patients stated that they always took their HF medications exactly as advised by the doctor (78.7%), or they never forgot to take their HF medicine (71.0%; Table 5).

Discussion

The results of this cross-sectional study characterizing the burden of HF patients from five major countries in Europe




Figure 1 Patients with heart failure who reported: **(A)** Current symptoms. **(B)** Most troublesome symptoms. **Abbreviation:** GI, gastrointestinal.

show that patients with HF and LVEF $\leq 60\%$ have impaired HRQoL. The HRQoL of women with HF was significantly lower compared with HRQoL of men with HF, including the aspects of physical and emotional health such as feelings of low mood/depression and anxiety. The activity impairment due to HF was significantly more in women vs men. Hospitalizations for any cause as well as due to HF were also higher among women compared with men. The overall findings indicate a higher burden of HF in women vs men.

Patients surveyed in this study were retired elderly patients with a median age of 70 years and a higher proportion were male. The baseline characteristics and comorbidities were consistent with those of other surveys/cross-sectional studies on chronic HF patients from Europe, as well as with those of other DSP™ HF studies.^{31–35} The occurrence of common and most

troublesome symptoms was also in line with that in previous studies.³⁶ The five most troublesome symptoms reported by the patients correlated with the most frequently reported symptoms, with the exception of shortness of breath when at rest, which frequently bothered patients despite not being the most common symptom. This is similar to the findings by Jackson et al in another DSP™ HF study.³³

The burden of disease seemed to be significantly different between the two genders, despite both groups reporting similar levels of disruption in their everyday life. More than half of the HF patients in this study had depression (54%) and anxiety (55%), with a higher occurrence observed among women vs men. Previous research suggests that depressive symptoms and anxiety are common in chronic HF patients.^{37,38} A meta-analysis of 36 studies showed that the mean prevalence rate of clinically




Figure 2 Patients with heart failure who reported: (A) Feelings of low mood/depression. (B) Feelings of anxiety.

significant depression among chronic HF patients was 21.5%³⁹ and was reported to vary with the type of study technique (questionnaires: 33.6%; diagnostic interview: 19.3%) and NYHA HF class (I: 11%; II: 20%; III: 38%; and IV: 42%).³⁹ Given that most patients in the present study belonged to NYHA classes II–IV, the depressive symptoms in more than half of the patients appeared to be consistent with those in published literature.³⁹ Although

the proportion of men and women in the less severe HF stages (ie, NYHA I and II) was equal, HRQoL was poorer among women vs men. The higher reporting of depression and anxiety among women compared with that in men may also be related to their baseline characteristics, since women were older and more likely to live alone. Previous research has shown that HF patients living alone are more prone to distress and social isolation leading to poor health outcomes.⁴⁰ Moreover, the studies characterizing depression and anxiety across genders in HF patients have consistently shown a higher occurrence of depression and anxiety among women vs men.^{9,41} Depressive symptoms have been shown to be a strong predictor of worsening health in HF patients⁴² and are associated with worse physical functioning, worse HF symptoms, increased hospitalizations, and increased mortality.^{37,38}

The HRQoL in the present study was assessed using MLHFQ, which is a widely used disease-specific HRQoL questionnaire validated for HF patients.^{24,43} We observed a mean overall MLHFQ score of 35.7, consistent with the overall (mean) MLHFQ scores reported in several studies from Europe^{44–47} ranging from 29.0⁴⁷ to 40.9.⁴⁶ Results suggested a significantly higher score (ie, poorer HRQoL) for women vs men (37.8 vs 34.5). The HRQoL of women with HF is consistently poorer vs men with HF, as reported by a meta-analysis of 15 studies with mean total MLHFQ scores of 45.6 and 40.7, respectively.⁴⁸ This trend was also found to be similar to that in clinical studies such as the PARAGON-HF trial in HF patients with an LVEF of

Table 2 MLHFQ and EQ-5D Scores for HRQoL of Patients with HF

Scale Score	Overall (N=804)	Men (n=517)	Women (n=287)	P-value
MLHFQ scale				
Overall score	N=624	n=401	n=223	
Mean (SD)	35.8 (21.4)	34.6 (21.6)	37.9 (20.9)	0.0481
Physical domain score	N=728	n=461	n=267	
Mean (SD)	17.4 (9.8)	16.6 (9.9)	18.6 (9.5)	0.0041
Emotional domain score	N=753	n=486	n=267	
Mean (SD)	8.4 (6.2)	7.9 (6.0)	9.4 (6.4)	0.0021
EQ-5D-5L scale				
Utility score	N=783	n=505	n=278	
Mean (SD)	0.73 (0.25)	0.75 (0.23)	0.69 (0.28)	0.0046
VAS score	N=783	n=502	n=281	
Mean (SD)	59.2 (19.1)	61.3 (18.4)	55.4 (19.7)	<0.0001

Notes: MLHFQ: higher score indicates a worse quality of life. Range for overall score is 0–105; physical, 0–40; emotional, 0–25. EQ5D-5L VAS: Lower score indicates poorer HRQoL. Range for VAS score is 0–100. The p values in bold indicate statistically significant difference ($p < 0.05$).

Abbreviations: EQ5D, European Quality of Life Scale 5-dimension; HF, heart failure; HRQoL, health-related quality of life; MLHFQ: The Minnesota Living With Heart Failure Questionnaire; SD, standard deviation; VAS; visual analog scale.

Table 3 Impact of HF on Activity Impairment and Work Productivity Among Patients with HF

WPAI Scale	Overall (N=804)	Men (n=517)	Women (n=287)	P-value
Percentage activity impairment due to HF Mean (SD)	N=725 43.2 (25.0)	n=464 41.4 (25.0)	n=261 46.4 (24.8)	0.01
Percentage impairment while working due to HF Mean (SD)	N=109 27.4 (23.0)	n=83 28.2 (23.0)	n=26 25.0 (23.0)	0.5384
Percentage work time missed due to HF Mean (SD)	N=108 9.6 (26.4)	n=83 10.7 (27.7)	n=25 5.6 (21.2)	0.3954
Percentage overall work impairment due to HF Mean (SD)	N=101 29.1 (24.5)	n=77 29.9 (24.7)	n=24 26.6 (24.2)	0.5684

Note: The p values in bold indicate statistically significant difference ($p < 0.05$).

Abbreviations: HF, heart failure; SD, standard deviation; WPAI, Work Productivity and Activity Impairment scale.

$\geq 45\%$.⁴⁹ Similar results were also seen for EQ-5D scores, with a significantly lower ($p=0.0046$) utility score among women vs men (0.69 vs 0.75), which is also in line with previous findings.^{49,50} As noted, HF impacted work productivity among working patients. Patients reported 43% of activity impairment due to HF, which was found to be consistent with a previous study.³³

A prior analysis from this study reporting symptoms and HRQoL of patients stratified into those with LVEF $<40\%$ and LVEF $\geq 40\text{--}60\%$ revealed that patient-reported symptoms of HF and baseline comorbidities were higher among patients with LVEF $<40\%$ compared to those with LVEF $\geq 40\text{--}60\%$. Also, the patients with LVEF $<40\%$ reported statistically significantly worse HRQoL compared to those with LVEF $\geq 40\text{--}60\%$.⁵¹ These findings were consistent with literature reporting lower HRQoL in patients with LVEF $<40\%$ compared to those with LVEF 40–49% and $>50\%$.⁵² The analysis from PARAGON-HF trial in patients with HF with median LVEF 57% showed that HRQoL assessed using Kansas City Cardiomyopathy Questionnaire was largely worse in women than men, and was similar in HFpEF and HFrEF after adjusting for potential confounding factors.⁴⁹ Our analysis was limited to stratification based on LVEF status of the patients - further subgroups based on sex within each LVEF category were not evaluated, and could be avenues for further research.

Patients in the present study had approximately five visits to a doctor owing to HF in the year prior to the survey. Approximately one-quarter of the patients were hospitalized in the last year owing to HF, and the mean number of HF hospitalizations was 0.35. These findings appeared to be consistent with those of our previous HF

DSPTM studies, which reported hospitalizations owing to HF in 30% of the patients with a mean number of HF hospitalizations of 0.40.⁵³ Worsening or uncontrolled symptoms of HF was the most common reason for HF hospitalizations. This clinical burden was also higher among women compared with that in men, although the differences were not statistically significant. A recently published retrospective, population-based study analyzing 20-year trends showed that although the number of hospitalizations owing to HF in 2012–2015 was similar across both genders (ie, 22 per 100 person-years), the annual increase in HF hospitalizations was 2.6% in women compared with stable rates in men (0.6%).⁵⁴ This means that hospitalizations owing to HF are likely to increase among women, which will ultimately lead to a greater clinical burden among them. Although the economic burden was not assessed in this study, the HF hospitalizations, visits to the doctor, and work productivity loss due to HF reported here pose a substantial financial burden on the healthcare system and society. Costs of hospital visits have been reported to comprise a major portion of the HF-related healthcare costs.⁸ Repeat HF hospitalizations account for 1–2% of the total direct healthcare expenditure of developed countries.^{8,55}

The 2016 ESC guidelines recommend the use of ACE inhibitors, angiotensin receptor blockers, β -blockers and mineralocorticoid-receptor antagonists in patients with HFrEF.¹ The use of sacubitril/valsartan to replace ACE inhibitors in ambulatory HFrEF patients who remain symptomatic despite optimal therapy is also recommended.¹ These medications can be used in conjunction with diuretics based on patients' symptoms and/or sign of congestion.¹ Of note, β -blockers, diuretics, and

Table 4 Clinical Burden of HF Based on Patient Record Form Data Completed by Physician

	Overall (N=804)	Men (n=517)	Women (n=287)	P-value
Number of times a patient visited a doctor in relation to HF condition in the last 12 months* Mean (SD)	N=770 4.7 (4.4)	n=493 4.6 (4.6)	n=277 4.9 (4.2)	0.4426
Number of hospitalization for any cause in the last 12 months, n (%)	N=667	n=419	n=248	0.1512
0	462 (69.3)	294 (70.2)	168 (67.7)	
1	137 (20.5)	89 (21.2)	48 (19.4)	
2	40 (6.0)	20 (4.8)	20 (8.1)	
3	15 (2.3)	7 (1.7)	8 (3.2)	
4	8 (1.2)	7 (1.7)	1 (0.4)	
5+	5 (0.8)	2 (0.5)	3 (1.2)	
Hospitalization for any cause in the last 12 months Mean (SD)	N=667 0.49 (0.97)	n=419 0.46 (0.97)	n=248 0.54 (0.99)	0.3484
Number of hospitalization due to HF in the last 12 months, n (%)	N=667	n=419	n=248	0.6766
0	511 (76.6)	324 (77.3)	187 (75.4)	
1	116 (17.4)	74 (17.7)	42 (16.9)	
2	25 (3.8)	14 (3.3)	11 (4.4)	
3	6 (0.9)	2 (0.5)	4 (1.6)	
4	5 (0.8)	3 (0.7)	2 (0.8)	
5+	4 (0.6)	2 (0.5)	2 (0.8)	
Hospitalization due to HF in the last 12 months Mean (SD)	N=667 0.35 (0.84)	n=419 0.32 (0.83)	n=248 0.38 (0.85)	0.3838
Hospitalization level data	N=268	n=166	n=102	
Reasons for HF related hospitalization in the last 12 months, n (%)	N=261	n=160	n=101	0.4634
Worsening/uncontrolled HF symptoms	207 (79.3)	124 (77.5)	83 (82.2)	
HF treatment side effects	5 (1.9)	2 (1.3)	3 (3.0)	
For surgery	18 (6.9)	12 (7.5)	6 (5.9)	
Other HF related reason	31 (11.9)	22 (13.8)	9 (8.9)	
Patients admitted through ER for HF related hospitalization in the last 12 months, n (%)	N=259	n=160	n=99	0.1918
Yes	192 (74.1)	114 (71.3)	78 (78.8)	
No	67 (25.9)	46 (28.7)	21 (21.2)	
Number of nights spent in hospital for HF related hospitalizations in the last 12 months Mean (SD)	N=193 5.3 (4.1)	n=118 5.5 (4.7)	n=75 4.9 (2.9)	0.3474

Note: *Data set is patient self-completion questionnaire.

Abbreviations: ER, emergency room; HF, heart failure; SD, standard deviation.

ACE inhibitors were the most commonly used treatments in the present study. There was no significant difference in the use of these treatments by sex. Patients were optimally treated in this study as suggested by the high compliance rates to their HF medications. Previous research has shown that higher medication adherence was associated with

reductions in emergency room visits, hospital admissions, length of hospital stay, and all-cause mortality.⁵⁶

The overall evidence suggests that HF has a substantial impact on patients' HRQoL, with women presenting with a poorer HRQoL than men. Women reported more impairment in physical and emotional health and were hospitalized more

Table 5 Compliance Among Patients with HF for the Treatments They Were Receiving

	Overall (N=804)	Men* (n=517)	Women* (n=287)
[†] In your experience, how compliant is this patient with their heart failure treatment, n (%)	N=750	n=483	n=267
Poor compliance (takes <50% of prescribed dose)	14 (1.87)	8 (1.66)	6 (2.25)
Fairly compliant (takes 50–80% of prescribed dose)	151 (20.13)	104 (21.53)	47 (17.60)
Fully compliant (takes >80% of prescribed dose)	581 (77.47)	370 (76.60)	211 (79.03)
[#] How often do you take your heart failure medicine exactly as advised by your doctor eg in relation to time and dose?, n (%)	N=759	n=489	n=270
All the time	597 (78.66)	387 (79.14)	210 (77.78)
[#] How often do you forget to take your heart failure medicine?, n (%)	N=753	n=484	n=269
Never	535 (71.05)	350 (72.31)	185 (68.77)
[#] If you feel better do you ever stop taking your heart failure medicine?, n (%)	N=753	n=484	n=269
All the time	10 (1.33)	8 (1.65)	2 (0.74)
[#] How often do you not get your heart failure medicine because it costs too much money?, n (%)	N=751	n=483	n=268
Never	655 (87.22)	418 (86.54)	237 (88.43)
[#] Do you fail to take your heart failure medicine because you do not like the way you have to take it, ie, tablet or injection?, n (%)	N=751	n=483	n=268
Never	651 (86.68)	414 (85.71)	237 (88.43)

Notes: *The p value for the difference between men and women was non-significant. [†] Physician reported. [#]Patient reported.

Abbreviation: HF, heart failure.

often despite having a higher mean LVEF than men. These aspects suggest that there are meaningful differences between men and women in HF progression and impact that need to be better understood to optimize patient care. Overall, there is a need for more effective treatments to ensure adequate control of HF symptoms and to reduce the HRQoL burden. The Heart Failure Policy Network in Europe⁸ focusing on improving the prevention, management, and care of HF recommends that HF should be a priority policy because (a) prevalence is increasing, (b) awareness is low and symptoms are not recognized by most people, (c) several of the HF cases could be prevented, (d) outcomes are poorer than several common cancers, (e) HF poses a considerable and growing healthcare burden to society, and (f) HF is managed suboptimally and significant disparities exist in management of HF.

This study has certain limitations. The sample may not represent the overall population of HF patients, as only eight consecutive suitable HF patients who consulted the physicians were included. This could have led to the inclusion of patients who consulted more frequently.

Although physician selection involved minimal exclusion criteria, the willingness of physicians to participate in the study and limitations of geographical location could have influenced their selection. Data collected in surveys of this type may be subject to recall bias by physicians and patients. Patient self-completion questionnaires were completed voluntarily; thus, they may reflect a more motivated subpopulation. No adjustments were made for patients' clinical characteristics for comparison between men and women. Therefore, the results reflect the differences observed in patients as seen in practice. Of note, women in the present study were significantly older and more frequently lived alone than men, and this could have impacted their burden of disease. Overall, Adelphi's DSPTM has a well-established methodology²³ for conducting cross-sectional survey studies in real-world settings.

Conclusion

In conclusion, evidence from this real-world study showed that patients with HF with an LVEF of ≤60% have

a reduced HRQoL and that HF presents substantial disruption to patients' everyday life in Europe. Importantly, this study shows that HF poses a higher burden and is associated with significantly lower HRQoL among women compared with men, including the aspects of physical and emotional health such as low mood/depression and anxiety. The burden of hospitalizations was also higher among women compared with that in men. These sex difference in the burden of disease is consistent with other studies in HF and warrants further investigation to better understand the underlying reasons and support optimal patient care.

Acknowledgments

Medical writing assistance was provided by Raju Gautam and Lovneet Saini, who are employees of Novartis Healthcare Pvt. Ltd., Hyderabad, India.

Funding

This study was funded by Novartis Pharma AG, Basel, Switzerland.

Disclosure

The abstract of this paper was presented at the European Society of Cardiology (ESC) Congress, August 29 – September 02, 2020 as a poster presentation with interim findings. The poster's abstract was published in European Journal of Heart Failure, Supplement: HFA Discoveries Abstract. 2020; 22(S1): <https://esc365.escardio.org/Presentation/223187/abstract>

A. F. Fonseca, R. Lahoz, C. Proudfoot, S. Corda and R. Studer are employees of Novartis Pharma AG, Basel, Switzerland. E. Loeferth was an employee of Novartis Pharma AG at the time of conduct of this study. J. Jackson and S. Cotton are employees of Adelphi Real World and were contracted by Novartis to conduct this study.

References

- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18:891–975.
- Milinković I, Giuseppe R, Lopatin Y, Seferović PM. The role of ivabradine and trimetazidine in the new ESC HF guidelines. *Cardiac Failure Rev*. 2016;2:123.
- Westenbrink BD, Brugts JJ, McDonagh TA, Filippatos G, Ruschitzka F, Van Laake LW. Heart failure specialization in Europe. *Eur J Heart Fail*. 2016;18:347–349. doi:10.1002/ehf.506
- Khavjou O, Phelps D, Leib A. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035. Technical report; 2016. Available from: <https://healthmetrics.heart.org/wp-content/uploads/2017/10/Projections-of-Cardiovascular-Disease.pdf>. Accessed July 8, 2021.
- Jeon YH, Kraus SG, Jowsey T, Glasgow NJ. The experience of living with chronic heart failure: a narrative review of qualitative studies. *BMC Health Serv Res*. 2010;10:77. doi:10.1186/1472-6963-10-77
- Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). *Circ Cardiovasc Qual*. 2010;3:573–580. doi:10.1161/CIRCOUTCOMES.110.957571
- Norberg EB, Boman K, Löfgren B. Activities of daily living for old persons in primary health care with chronic heart failure. *Scand J Caring Sci*. 2008;22:203–210. doi:10.1111/j.1471-6712.2007.00514.x
- Heart Failure Policy Network; 2020. Heart failure policy and practice in Europe. London: HFPN. Available from: <https://www.healthpolicypartnership.com/app/uploads/Heart-failure-policy-and-practice-in-Europe.pdf>.
- Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van Veldhuisen DJ, Sanderma R. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. *J Card Fail*. 2009;15:17–23. doi:10.1016/j.cardfail.2008.09.006
- Broström A, Strömberg A, Dahlström U, Fridlund B. Sleep difficulties, daytime sleepiness, and health-related quality of life in patients with chronic heart failure. *J Cardiovasc Nurs*. 2004;19:234–242. doi:10.1097/00005082-200407000-00003
- Cowie MR, Anker SD, Cleland JG, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. *ESC Heart Fail*. 2014;1:110–145.
- Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. *Eur J Heart Fail*. 2005;7:243–251. doi:10.1016/j.ejheart.2005.01.012
- Faxén UL, Hage C, Donal E, Daubert JC, Linde C, Lund LH. Patient reported outcome in HFpEF: sex-specific differences in quality of life and association with outcome. *Int J Cardiol*. 2018;267:128–132. doi:10.1016/j.ijcard.2018.04.102
- Friedman MM. Gender differences in the health related quality of life of older adults with heart failure. *Heart Lung*. 2003;32:320–327. doi:10.1016/S0147-9563(03)00098-0
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet (London, England)*. 2003;362(9386):777–781. doi:10.1016/S0140-6736(03)14285-7
- Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Nephrilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *NEJM*. 2019;381:1609–1620. doi:10.1056/NEJMoa1908655
- Lam CSP, Voors AA, Piotr P, McMurray JJV, Solomon SD. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. *Eur Heart J*. 2020;41:2353–2355. doi:10.1093/eurheartj/ehaa158
- Triposkiadis F, Butler J, Abboud FM, et al. The continuous heart failure spectrum: moving beyond an ejection fraction classification. *Eur Heart J*. 2019;40:2155–2163. doi:10.1093/eurheartj/ehz158
- Novartis Entresto granted expanded indication in chronic heart failure by FDA; February 16, 2021. Available from: <https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda>. Accessed June 21, 2021.

20. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *NEJM*. 2014;371:993–1004. doi:10.1056/NEJMoa1409077
21. Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. *BMJ Open*. 2016;6:e010352. doi:10.1136/bmjopen-2015-010352
22. Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. *Diabetes Metab Syndr Obes Targets Ther*. 2016;9:371–380. doi:10.2147/DMSO.S120101
23. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-Specific Programmes - a means to understand. *Curr Med Res Opin*. 2008;24:3063–3072. doi:10.1185/03007990802457040
24. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. *Heart Fail*. 1987;3:198–209.
25. EuroQol—a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands). 16:199–208; 1990.
26. Brooks R. EuroQol: the current state of play. *Health Policy (Amsterdam, Netherlands)*. 1996;37:53–72. doi:10.1016/0168-8510(96)00822-6
27. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20:1727–1736. doi:10.1007/s11136-011-9903-x
28. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. *Health Qual Life Outcomes*. 2010;8:13. doi:10.1186/1477-7525-8-13
29. National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L valuation set for England; Updated October 2019. Available from: <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l>. Accessed September 15, 2020.
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*. 1993;4:353–365. doi:10.2165/00019053-199304050-00006
31. Brugts JJ, Linssen GCM, Hoes AW, Brunner-la Rocca HP. Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. *Neth Heart J*. 2018;26:272–279. doi:10.1007/s12471-018-1103-7
32. van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. *Eur J Heart Fail*. 2014;16:103–111. doi:10.1002/ehf.30
33. Jackson JD, Cotton SE, Bruce Wirta S, et al. Burden of heart failure on patients from China: results from a cross-sectional survey. *Drug Des Devel Ther*. 2018;12:1659–1668. doi:10.2147/DDDT.S148949
34. Wirta SB, Balas B, Proenca CC, et al. Perceptions of heart failure symptoms, disease severity, treatment decision-making, and side effects by patients and cardiologists: a multinational survey in a cardiology setting. *Ther Clin Risk Manag*;2018. 2265–2272. doi:10.2147/TCRM.S183200
35. Jackson JD, Cotton SE, Bruce Wirta S, et al. Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey. *Drug Des Devel Ther*. 2018;12:2311–2321. doi:10.2147/DDDT.S166277
36. Wilson J, McMillan S. Symptoms Experienced by Heart Failure Patients in Hospice Care. *J Hosp Palliat Nurs*. 2013;15:13–21. doi:10.1097/NJH.0b013e31827ba343
37. Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and Anxiety in Heart Failure: a Review. *Harv Rev Psychiatry*. 2018;26:175–184. doi:10.1097/HRP.0000000000000162
38. Liguori I, Russo G, Curcio F, et al. Depression and chronic heart failure in the elderly: an intriguing relationship. *J Geriatr Cardiol*. 2018;15:451–459.
39. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol*. 2006;48:1527–1537. doi:10.1016/j.jacc.2006.06.055
40. Polikandrioti M, Panoutsopoulos G, Tsami A, et al. Assessment of quality of life and anxiety in heart failure outpatients. *Arch Med Sci Atheroscler Dis*. 2019;4:e38–e46. doi:10.5114/amsad.2019.84444
41. Lesman-Leegte I, Jaarsma T, Sanderma R, Linssen G, van Veldhuisen DJ. Depressive symptoms are prominent among elderly hospitalised heart failure patients. *Eur J Heart Fail*. 2006;8:634–640. doi:10.1016/j.ejheart.2005.11.010
42. Rumsfeld JS, Havranek E, Masoudi FA, et al. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. *J Am Coll Cardiol*. 2003;42:1811–1817. doi:10.1016/j.jacc.2003.07.013
43. Bilbao A, Escobar A, García-Pérez L, Navarro G, Quirós R. The Minnesota living with heart failure questionnaire: comparison of different factor structures. *Health Qual Life Outcomes*. 2016;14:23. doi:10.1186/s12955-016-0425-7
44. Årestedt K, Saveman BI, Johansson P, Blomqvist K. Social support and its association with health-related quality of life among older patients with chronic heart failure. *Eur J Cardiovasc Nurs*. 2013;12:69–77. doi:10.1177/1474515111432997
45. de Rivas B, Permanyer-Miralda G, Brotons C, Aznar J, Sobreviela E. Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: the INCA study. *Qual Life Res*. 2008;17:1229–1238. doi:10.1007/s11136-008-9397-3
46. Gallagher AM, Lucas R, Cowie MR. Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach. *ESC Heart Fail*. 2019;6:3–9. doi:10.1002/ehf2.12363
47. Lupón J, Gastelurrutia P, de Antonio M, et al. Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. *Eur J Heart Fail*. 2013;15:103–109. doi:10.1093/eurjhf/hfs133
48. Moradi M, Daneshi F, Behzadmehr R, Rafiemanesh H, Bouya S, Raeisi M. Quality of life of chronic heart failure patients: a systematic review and meta-analysis. *Heart Fail Rev*. 2019.
49. Chandra A, Vaduganathan M, Lewis EF, et al. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: the PARAGON-HF Trial. *JACC Heart Fail*. 2019;7:862–874. doi:10.1016/j.jchf.2019.05.015
50. Comin-Colet J, Anguita M, Formiga F, et al. Health-related Quality of Life of Patients With Chronic Systolic Heart Failure in Spain: results of the VIDA-IC Study. *Rev Esp Cardiol (Engl Ed)*. 2016;69:256–271. doi:10.1016/j.recsep.2015.07.034
51. Proudfoot C, Fonseca AF, Lahoz R, et al. Patients with heart failure and a LVEF less than 40% present an overall lower health related quality of life than those with LVEF between 40% and 60%: a multinational real-world survey in EU. *Eur Heart J*. 2020;41 (Supplement_2). doi:10.1093/ehjci/ehaa946.0974
52. Chen X, Xin Y, Hu W, et al. Quality of life and outcomes in heart failure patients with ejection fraction in different ranges. *PLoS One*. 2019;14(6). doi:10.1371/journal.pone.0218983
53. Karpf E, Jackson J, Cotton S, et al. Assessing the Burden of Chronic Heart Failure on Patients in Colombia. *Value Health*. 2017;20:A623. doi:10.1016/j.jval.2017.08.1362

54. Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. *Lancet Public Health*. 2019;4:e406–e20. doi:10.1016/S2468-2667(19)30108-2
55. Guha K, McDonagh T. Heart failure epidemiology: european perspective. *Curr Cardiol Rev*. 2013;9:123–127. doi:10.2174/1573403X11309020005
56. Hood SR, Giazson AJ, Seamon G, et al. Association between medication adherence and the outcomes of heart failure. *Pharmacotherapy*. 2018;38:539–545. doi:10.1002/phar.2107

Patient Preference and Adherence

Dovepress

Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal that focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease

states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/patient-preference-and-adherence-journal>